HISTORICAL FACTS: Apogee therapeutics | History Defined

AbbVie's Humira Era Is Fading, But Its New Growth Engines Face Another Test

AbbVie posted Q3 revenue of $17.4 billion and raised EPS guidance as Skyrizi and Rinvoq offset Humira's decline, prompting analyst price target hikes and a stock move to fresh highs.

MarketBeat · 6h ago

AbbVie Quietly Solved Its Biggest Problem—Now What?

AbbVie posted strong Q2 revenue and EPS growth, and despite a post-earnings dip tied to the Apogee Therapeutics deal, analysts and dividend strength support shares reaching $300.

MarketBeat · Aug 2

AbbVie Just Sparked a 46% Rally in Apogee. Here’s Why This $10.9 Billion Deal Could Be a Win for AbbVie Investors.

Apogee’s rally may be over, but AbbVie’s upside from the deal could just be getting started.

Barchart · Jun 23

US stocks drift near their records after oil prices fall

U.S. stocks are drifting near their records after trading resumed following a three-day weekend

AAP · Jun 22

Apogee Therapeutics Readies Zumi for Phase 3 With Blackstone Backing

Apogee Therapeutics (NASDAQ:APGE) executives said the company is preparing to move its lead drug candidate, zumilokibart, into Phase 3 testing later this year after reporting Phase 2b data in atopic dermatitis and securing a major financing agreement with Blackstone. Speaking at a Jefferies-hosted

MarketBeat · Jun 4

Top 2 Health Care Stocks That May Plunge This Month

As of July 7, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Benzinga · Jul 7, 2025

Why Apogee Therapeutics Shares Are Trading Higher By 50%; Here Are 20 Stocks Moving Premarket

Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) rose sharply in today's pre-market trading after the company disclosed positive 16-week data from Phase 2 APEX clinical trial of APG777, its potentially best-in-class anti-IL-13 antibody, in moderate-to-severe atopic dermatitis.

Benzinga · Jul 7, 2025

2 Russell 2000 Stocks With More Than 29% Upside Potential to Grab Now

Wall Street rates both of these outperforming small-cap stocks a “strong buy," with 29% or more upside expected over the next year.

Barchart · Mar 25, 2024

5 Russell 2000 Stocks Outperforming the 'Magnificent Seven' in 2024

The "Magnificent Seven" have lost some momentum in 2024, just as small-caps are starting to come on strong. Here's a closer look at five Russell 2000 stocks that are crushing the performance of their mega-cap peers so far this year.

Barchart · Mar 13, 2024